Evidence-Based Pediatric Oncology (eBook)

Ross Pinkerton, A. G. Shankar, Katherine Matthay (Herausgeber)

eBook Download: EPUB

2013 | 3. Auflage
John Wiley & Sons (Verlag)
978-1-118-62517-0 (ISBN)

Infos

Edited by
Ross Pinkerton, MB, BCh, BaO, MD, Executive Director, Division of Oncology, Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

Ananth Shankar, MD, FRCPCH, Consultant in Paediatric and Adolescent Oncology, University College
London Hospitals NHS Foundation Trust, London, UK

Katherine K. Matthay, BA, MD, Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology, Department of Pediatrics, UCSF School of Medicine and UCSF Benioff Children's Hospital, San Francisco, CA, USA

---

The new and updated edition of the renowned reference for pediatric oncologists This groundbreaking text on the management of childhood cancers covers most tumor types occurring in children and young adults and provides reviews of randomized trials with commentaries on the optimum treatments for childhood cancer. Updated with evidence from the latest published reviews and even more clinically focused than previous editions Evidence-Based Pediatric Oncology, Third Edition places an emphasis on application of the trial findings. With increased coverage of the area of supportive care for pediatric cancer patients, each chapter opens with an expert commentary on the key clinical issues followed by a summary of trial findings. Evidence-Based Pediatric Oncology, Third Edition: Presents evidence for the best treatment of children and adolescents with cancer Includes commentaries from the world s leading experts for every topic discussed Is internationally relevant thanks to contributions from the UK, US, Canada and Australia Places greater emphasis on supportive care and features a new extended section on antibiotic and antifungal treatments Based on information gathered from randomized trials performed after the release of the Second Edition, readers will find Evidence-Based Pediatric Oncology to be an important resource for all those treating young people with cancer.

Inhalt

List of contributors, vii

Preface, ix

List of abbreviations, x

About the companion website, xv

Part 1: Solid tumors

1 Rhabdomyosarcoma, 3
Katherine K. Matthay

(Commentary by Meriel Jenney)

2 Osteosarcoma, 14
Katherine K. Matthay

(Commentary by Maria Michelagnoli)

3 Ewing sarcoma, 25
Katherine K. Matthay

(Commentary by Steven G. DuBois)

4 Wilms tumor, 34
Ananth Shankar

(Commentary by Kathy Pritchard-Jones)

5 Neuroblastoma, 47
Katherine K. Matthay

(Commentary by Katherine K. Matthay)

6 Hepatoblastoma, 58
Ross Pinkerton

(Commentary by Penelope Brock)

7 Malignant germ cell tumors, 65
Ross Pinkerton

(Commentary by Ross Pinkerton)

8 Medulloblastoma, 69
Ross Pinkerton

(Commentary by Eric Bouffet)

9 Glioma, 81
Ross Pinkerton

(Commentary by Joann L. Ater)

10 Non-Hodgkin lymphoma, 88
Ross Pinkerton

(Commentary by Ross Pinkerton)

11 Hodgkin lymphoma, 105
Ross Pinkerton

(Commentary by Cindy L. Schwartz)

Part 2: Leukemia

Section 1: Acute myeloid leukemia 12 Acute myeloid leukemia commentary, 119
Robert J. Arceci

13 Remission induction in acute myeloid leukemia, 126
Ananth Shankar

14 Acute myeloid leukemia consolidation, 135
Ananth Shankar

15 Maintenance treatment in acute myeloid leukemia, 137
Ananth Shankar

16 Autologous bone marrow transplantation in acute myeloid leukemia, 141
Ananth Shankar

17 Acute myeloid leukemia: miscellaneous, 144
Ananth Shankar

Section 2: Childhood lymphoblastic leukemia

18 Childhood lymphoblastic leukemia commentary, 146
Vaskar Saha

19 Remission induction in childhood lymphoblastic leukemia, 154
Ananth Shankar

20 Central nervous system-directed therapy in childhood lymphoblastic leukemia, 168
Ananth Shankar

21 Maintenance treatment in childhood lymphoblastic leukemia, 180
Ananth Shankar

22 Relapsed childhood lymphoblastic leukemia, 198
Ananth Shankar

23 Postinduction therapy in adolescents and young adults with acute lymphoblastic leukemia, 204
Ananth Shankar

Part 3: Supportive care in pediatric oncology

24 Colony-stimulating factors, 209
Ananth Shankar

(Commentary by Victoria Grandage)

25 Cardioprotection in pediatric oncology, 230
Ananth Shankar

(Commentary by Gill A. Levitt)

26 Infections in pediatric and adolescent oncology, 243
Ananth Shankar and Sara Stoneham

(Commentary by Julia E. Clark)

Index, 269

Textauszug

List of abbreviations

6-MP	6-mercaptopurine

6-TG	6-thioguanine

AA	anaplastic astrocytoma

ABMT	autologous bone marrow transplantation

ABVD	doxorubicin, bleomycin, vinblastine, dacarbazine

ABVE	doxorubicin, bleomycin, vincristine, etoposide

ABVE-PC

doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide

ACOMP

doxorubicin, cyclophosphamide, vincristine, methylprednisolone, prednisone

ACOP	doxorubicin, cyclophosphamide, vincristine, prednisone

ACT-D

actinomycin D

AE	adverse events

AFP	α-fetoprotein

ALCL	anaplastic large cell lymphoma

ALK	anaplastic lymphoma kinase

ALL	acute lymphoblastic leukemia

allo-BMT

allogeneic bone marrow transplantation

allo-SCT

allogeneic stem cell transplantation

ALPN	allopurinol

ALT	alanine aminotransferase

AML	acute myeloid leukemia

ANC	absolute neutrophil count

AOP	doxorubicin, vincristine, prednisone

AP	Adriamycin/cisplatin

APL	acute promyelocytic leukemia

APTT	activated partial thromboplastin time

ARAC	cytosine arabinoside

ASCO	American Society of Clinical Oncology

ASCT	autologous stem cell transplant

ASN	asparagine

ASP	asparaginase

AST	aspartate aminotransferase

ATRA	all-trans-retinoic acid

AVA	doxorubicin plus vincristine and actinomycin (VA)

B-ALL

B-cell acute lymphoblastic leukemia

BCD	cisplatin or bleomycin, cyclophosphamide, actinomycin D

BEP	bleomycin, etoposide, cisplatin

BFM	Berlin-Frankfurt-Münster

BL	Burkitt lymphoma

BLL	Burkitt-like lymphoma

BM	bone marrow

BMT	bone marrow transplant

BNHL	B-cell non-Hodgkin lymphoma

BuMel

busulfan and melphalan

CAA	cancer-associated anemia

CAI	catheter-associated infection

CALGB

Cancer and Leukemia Group B

cALL	common acute lymphoblastic leukemia

CC	continuation chemotherapy

CCF	congestive cardiac failure

CCR	continuous clinical remission

CCSG	Children’s Cancer Study Group

CCSK	clear cell sarcoma of kidney

CDI	chemotherapy dose intensity

CDR	clinical decision rules

CEM	melphalan, etoposide, carboplatin

CFRT	conventional fractionated radiotherapy

CHF	congestive heart failure

CHOP	cyclophosphamide, doxorubicin, vincristine, prednisone

CI	confidence interval, cumulative incidence

CLDB	cladribine

CML	chronic myeloid leukemia

CNS	central nervous system

COG	Children’s Oncology Group

COJEC

cisplatin, vincristine, carboplatin, etoposide, cyclophosphamide

COMP	cyclophosphamide, vincristine, methotrexate, prednisone

COP	cyclophosphamide, vincristine, prednisolone

COPAD

cyclophosphamide, vincristine, prednisone, doxorubicin

COPAdM

cyclophosphamide, vincristine, prednisolone, doxorubicin, and high-dose methotrexate with intrathecal methotrexate

COPP	cyclophosphamide, vincristine, prednisone, procarbazine

CR	complete remission/response

CRBSI

catheter-related bloodstream infection

CRT	cranial irradiation

CS	craniospinal

CsA	cyclosporine A

CSF	cerebrospinal fluid; colony-stimulating factor

CSRT	craniospinal radiotherapy

CT	chemotherapy; computed tomography; continuing therapy

CVC	central venous catheter

CVPP	cyclophosphamide, vincristine, procarbazine, prednisone

DA	daunorubicin and ARA-C

DAT	daunomycin, cytarabine, thioguanine

DD	divided dose

DEX	dexamethasone

DFCI	Dana-Farber Cancer Institute

DFS	disease-free survival

DI	delayed intensification

DIPG	diffuse intrinsic pontine glioma

DLBCL

diffuse large B-cell lymphoma

DLCL	diffuse large cell lymphoma

DMC	data monitoring committee

DNPS	de novo purine synthesis

DNR	daunorubicin

DT	disproportionate thrombocytopenia

ECHO	echocardiography

ECOG	Eastern Co-operative Oncology Group

EF	extended field

EFS	event-free survival

EOI	European Osteosarcoma Intergroup

EORTC

European Organization for Research into Treatment of Cancer

EPO	erythropoietin

EpSSG

European Paediatric Soft Tissue Sarcoma Group

ETPALL

early T precursor acute lymphoblastic leukemia

EVAIA

vincristine, doxorubicin, dactinomycin, ifosfamide with the addition of etoposide

FBN	febrile neutropenia

FDG-PET

fluorodeoxyglucose positron emission tomography

FFS	failure-free survival

FH	favorable histology

FLAG-Ida

fludarabine, cytarabine, GCSF, idarubicin

FUO	fever of unknown...

Produkt-Details

• Erscheint lt. Verlag: 19.2.2013
• Reihe/Serie: Evidence-Based Medicine
• Reihe/Serie: Evidence-Based Medicine
• Reihe/Serie: Evidence-Based Medicine
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Allgemeines / Lexika
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pädiatrie
• Schlagworte: application • Childhood • clinically • Edition • Editions • Evidence • Evidence-based Health Care • evidencebased pediatric • Evidenzbasierte Forschung im Gesundheitswesen • Evidenzbasierte Medizin • Focused • groundbreaking • Latest • Management • Medical Science • Medizin • New • oncologists • Oncology • Pädiatrische Onkologie • Pädiatrische Onkologie • Pediatric • Places • previous • published • Reference • renowned • reviewsand • Trial
• ISBN-10: 1-118-62517-X / 111862517X
• ISBN-13: 978-1-118-62517-0 / 9781118625170